Objective-Atherosclerosis is the primary driver of cardiovascular disease, the leading cause of death worldwide.
C ardiovascular disease, the leading cause of death worldwide, 1 accounts for 1 in 3 deaths in the United States 1 and is primarily driven by atherosclerosis. Initiation of atherosclerosis is thought to stem from a confluence of injury to the endothelium along with lipid deposition in the vascular wall, which then triggers an ongoing cycle of endothelial cell (EC) activation, inflammatory cell infiltration, hyperplastic vascular smooth muscle cell (VSMC) proliferation, and further lipid accumulation. 2 Atherosclerosis progression ultimately results in a toxic microenvironment in which dead or dying lipid-laden foam cells are sequestered from the circulation by a VSMC-derived fibrous cap. 2, 3 Atheroprotective genes or factors that delay the initiation or progression of the atheroma are of great interest for their potential to delay adverse events. 4 We sought to identify novel, potentially atheroprotective genes in a previous study, in which we conducted a transcript screen for alternately regulated genes in human arteries versus veins and other tissues. 5 The most strongly upregulated of the significantly altered genes was the small proline-rich repeat protein 3 (SPRR3), a member of the SPRR family. Interestingly, immunofluorescence staining of human thoracic aorta showed that, although expression was high in atheroma, no SPRR3 expression was detected in healthy arterial tissue. 5 SPRRs are primarily expressed in cornified envelope and stratified epithelium such as skin and, in the case of SPRR3, foregut and esophagus. 6 Interestingly, some studies have shown that SPRR3 is also associated with prosurvival functions in colorectal cancer. 7 However, the mechanism by which SPRR3 promotes cell survival remains undetermined. We have previously investigated the mechanism by which SPRR3 is expressed specifically in VSMCs within atheromas. The mechanism of SPRR3 expression in atherosclerotic plaques requires both cyclic strain and the expression of integrin α 1 β 1 , a major receptor for collagen type I; VSMCs isolated from integrin α 1 β 1 knockout mice failed to upregulate SPRR3 transcripts under cyclic strain. 8 We confirmed that VSMCs within atheromas expressed integrin α 1 β 1 [8] [9] . SPRR3 may, therefore, represent a VSMC-derived response to the atheroma microenvironment.
To elucidate the pathophysiological function of SPRR3 in the atheroma, we developed an SPRR3-deficient mouse bred onto an atherogenic apolipoprotein E-deficient (ApoE −/− ) background. Here, we have provided evidence for SPRR3 as an atheroprotective factor that operates specifically in the atheroma and promotes VSMC survival. We also uncovered a novel role for SPRR3 as an atheroprotective protein that regulates lesion development via interaction with the Akt signaling pathway in atheroma VSMCs.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Atherosclerosis Is Increased in ApoENull Mice Lacking SPRR3
We have shown previously that arterial SPRR3 is expressed in humans and mice at sites of lesion development. 5, 8 We verified the atheroma expression pattern of SPRR3 in aortic root atheroma sections from 6-month-old ApoE-null mice fed normal diet immunostained for both SPRR3 and a VSMC-specific marker (smooth muscle α-actin [α-SMA]). SPRR3 colocalized with α-SMA, indicating that expression was primarily found in VSMCs ( Figure 1A) . A comparison of SPRR3 transcript levels in atheroma-bearing arterial tissue versus normal arterial tissue indicated a 9-fold increase (P=0.02) in SPRR3 mRNA expression ( Figure 1B) .
To investigate the role of SPRR3 in atherosclerotic lesions, we generated SPRR3 knockout mice ( Figure IA to IC in the online-only Data Supplement). SPRR3 knockout mice were overtly phenotypically normal and reproduced normally compared with wild-type (WT) C57Bl/6 mice. Serum cholesterol and triglyceride levels ( Table I in the online-only Data Supplement; n=6), as well as body weight measurements, were comparable with WT. The lack of an associated phenotype in SPRR3 knockout mice was expected, because of the near total absence of atheroma formation in WT mice with normal lipid profiles. Therefore, we crossed SPRR3 knockout mice onto the atherogenic ApoE-null background. We assessed atherosclerosis severity in 6-month-old ApoE-null (SPRR3 ) mice fed normal chow (4.5% fat by weight with 13% of calories derived from fat, diet 5001; PMI, St Louis, MO). Serum triglyceride and cholesterol levels did not differ between groups (Table I in the online-only Data Supplement; n=6).
To determine whether SPRR3 loss alters atherosclerosis progression, we compared the extent of atherosclerosis in 6-month-old sex-matched DKO mice with ApoE-null control mice fed a normal chow diet. We used Sudan IV to quantify atherosclerosis by en face analysis of aortas, in which DKO mice exhibited a 3-fold increase in lesion area over control (0.7±0.14% in SPRR3 Figure IIA and IIB in the online-only Data Supplement; DKO increased 51% over ApoE-null, P=0.03). To determine whether the increased atheroma burden observed on normal chow would be maintained on an atherogenic diet, we fed ApoE-null and DKO mice a high-fat diet (9% fat by weight with 21% of calories derived from fat, diet 5021; PMI, St Louis, MO) for 6 months. After the atherogenic diet, a 3-fold greater lesion area was observed in DKO aortas than in ApoE-null aortas (2.3±0. 
VSMC Survival Is Selectively Reduced in Atheromas of SPRR3-Deficient Mice
Because SPRR3 expression was primarily observed in atheroma VSMCs, we sought to determine whether VSMC localization or content was altered in mice lacking SPRR3. An initial stain with anti-α-SMA of aortic root sections from mice fed normal chow suggested DKO mice had lower α-SMA-positive VSMC content than age-matched ApoE-null mice ( Figure 3A) . To quantify the change in lesion VSMC content, we collected confocal images of anti-α-SMA-stained and anti-smooth muscle myosin heavy chain-stained aortic root sections from DKO and ApoE-null mice fed normal chow ( Figure 3B and 3C). VSMC content was quantified as the number of α-SMA-positive or smooth muscle myosin heavy chain-positive cells normalized to plaque cellularity (cells/mm 2 ). α-SMA-positive staining indicated that DKO (n=8) lesions had a 37.3% (P<0.001) reduction in lesion VSMC content compared with control (n=8; Figure 3D ). Similar results were observed in smooth muscle myosin heavy chain-stained sections ( Figure IV in the online-only Data Supplement; P=0.0001; n=3 per group). When VSMC content was quantified in DKO and ApoE-null mice fed high-fat diet for 6 months, lesion VSMC content was reduced by 48.1% (P=0.002) in mice lacking SPRR3.
The reduced atheroma VSMC content in mice lacking SPRR3 could be because of an increase in lesion VSMC cell death or a reduction in proliferation. To determine whether the reduced VSMC content was related to VSMC survival, we compared VSMC death in aortic root lesions of ApoEnull and DKO mice after 6 months on a high-fat diet. In the aortic root, the number of fibrous cap cells costaining for 
Increased Atherosclerosis in ApoE-Null Mice Lacking SPRR3 Is Not Attributable to Bone Marrow-Derived Cells
Because SPRR3 expression was primarily but not exclusively detected in VSMCs 8 ( Figure 1A ), we sought to identify the affected cell type(s) driving increased atheroma burden in mice with global SPRR3 deficiency. As macrophages are the primary source of foam cells in murine atherosclerosis, 10, 11 assessments of plaque burden that rely on lipid staining may reflect changes in macrophage recruitment or foam cell formation. We therefore evaluated changes in macrophage content relative to lesion size in aortic root lesions of ApoE-null and DKO mice fed high-fat diet for 4 months. Macrophage content was quantified by MOMA-2 staining, which binds an intracellular target in mouse monocytes and macrophages. Although absolute MOMA-2-positive area was increased in DKO mice, after controlling for lesion size, there was no significant difference in MOMA-2-positive staining between ApoE-null (47.9±6.2%) and DKO (34.3±2.1%) aortic roots (Figure 4A and 4B; n=8; P=0.14). Similarly, there was no significant difference in CD3-positive staining, an indicator of T-cell content, between ApoE-null (8.07±3.38%) and DKO (11.4±0.94%) aortic roots (P=0.06) after controlling for lesion size. These data suggested the SPRR3-dependent increase in atheroma burden observed in DKO mice was not mediated by bone marrow (BM)-derived cells.
To further confirm that the effects of SPRR3 loss were mediated through arterial, rather than BM-derived cells, we performed BM transplantation experiments. BM from ApoE-null (SPRR3 +/+ ApoE −/− ), SPRR3 knockout (SPRR3 −/− ApoE +/+ ), or DKO (SPRR3 −/− ApoE −/− ) donor mice was transplanted into 2-week-old lethally irradiated DKO-recipient mice. The experimental approach and anticipated results are explained in Figure 4C . After 4 months of high-fat diet, plaque burden was assessed in aortic root sections and in dissected aortas of each group. Previous studies have demonstrated that rescue of ApoE expression in the BM compartment of ApoE-null mice is sufficient to reduce lesion burden. 12 We therefore expected that DKO recipients of SPRR3 −/− ApoE +/+ donor cells (positive control) would exhibit significantly reduced atheroma burden compared with DKO recipients of DKO donor cells (negative control). Should the effects of SPRR3 on atherosclerosis be mediated through the BM compartment, we expected that transplant of SPRR3 (Figure 4D and 4E) . En face analysis of dissected aortas showed an 81.3% (P<0.01) reduction in aortic surface area covered by Sudan IV lipid stain ( Figure 4F and 4G) after ApoE +/+ BM transplantation and no significant difference in SPRR3 +/+ BM transplantation recipients. These data demonstrated that increased atherosclerosis observed in DKO mice was not mediated by BM-derived cells but instead by arterial cells. Quantitative reverse transcriptase polymerase chain reaction analysis of SPRR3 transcript expression in ECs isolated from WT C57Bl/6 mice showed little to no SPRR3 transcript expression. These data suggested that altered atheroma pathophysiology in SPRR3-deficient mice was not because of changes in EC function.
EC Survival and Proliferation
To investigate whether increased atheroma burden was associated with an effect of SPRR3 loss on VSMC function, we generated conditionally immortalized VSMCs that were WT or null for SPRR3 expression. Although SPRR3 protein was undetectable in VSMCs at baseline consistent with our previous publications, 8 we detected mRNA transcript expression in VSMCs with WT SPRR3 ( Figure VIID in the onlineonly Data Supplement).
Loss of SPRR3 Reduces VSMC Survival
To determine the role of SPRR3 in VSMC survival, we isolated primary VSMCs from SPRR3-KO (SPRR3
) and WT (C57Bl/6) mice for culture under cyclic strain. As described in our previous work, cyclic strain causes upregulation of SPRR3 expression in VSMCs in vitro. 8 VSMCs were transferred to collagen-I-treated elastomer membranes and subjected to 72 hours of cyclic strain to promote SPRR3 expression. Treatment with 0.5 mmol/L H 2 O 2 for 2 hours resulted in a 54.4±0.23% increase in TdT labeling in primary SPRR3-KO VSMCs as measured by TUNEL staining compared with primary WT VSMCs ( Figure 5A ; P=0.02), whereas no difference was observed in unchallenged groups under strain or between WT VSMCs and SPRR3-KO VSMCs not exposed to cyclic strain ( Figure VIIIA and VIIIB in the online-only Data Supplement). This finding demonstrated a protective role for SPRR3 in VSMCs exposed to oxidative stress under cyclic strain.
SPRR3-Overexpressing VSMCs Exhibit Reduced Apoptosis and Proliferation
If loss of SPRR3 leads to increased VSMC apoptosis, we hypothesized a prosurvival phenotype would be observed with SPRR3 overexpression. To generate SPRR3-overexpressing VSMCs, we isolated VSMCs from transgenic H-2K b -tsA58 mice that we then retrovirally transfected with LZRS plasmid expressing GFP (green fluorescent protein) alone (GFP-VSMCs) or expressing human SPRR3 and GFP (SPRR3-VSMCs). Cells from the H-2K b -tsA58 mouse expressing heat-labile T-antigen behind the mouse major histocompatibility complex H-2K b are immortalized at 33°C and return to primary phenotype after a week at 37°C. We evaluated the effect of SPRR3 overexpression on VSMC survival using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye reduction assays in serumstarved cells and both immunoblot and immunocytochemical staining analysis of active caspase-3 expression in cells exposed to oxidative stress. MTT dye reduction assays conducted under serum deprivation conditions indicated a 20% increase (P=0.03) in survival of SPRR3-VSMCs compared with control GFP-VSMCs ( Figure 5B ). This increase in VSMC viability observed with SPRR3 overexpression was not because of increased proliferation. WT-VSMCs and SPRR3-KO VSMCs treated with BrdU stain revealed no significant difference in proliferation of VSMCs lacking SPRR3 when compared with control VSMCs ( Figure IX in the online-only Data Supplement; P=0. 43) . To determine whether the increase in VSMC number observed in SPRR3-VSMCs was because of reduced apoptosis, we evaluated active caspase-3 levels by immunoblotting ( Figure 5C ) or immunofluorescence ( Figure 5D and 5E) after oxidative stress (via 0.25 mmol/L H 2 O 2 ), a proapoptotic trigger frequently observed in atherosclerotic lesions. Both methods demonstrated that SPRR3-VSMCs expressed less active caspase-3 in response to oxidative stress.
Akt Phosphorylation Is Increased in VSMCs Expressing SPRR3
A myriad of signaling changes takes place in VSMCs associated with plaque development and progression. Many of these signaling changes are associated with the functional changes observed in VSMCs during plaque progression (eg, proliferation, migration, synthesis of cap material) and with responses to novel interactions and stressors in the plaque microenvironment (eg, altered mechanical strain, proinflammatory signals, ROS [reactive oxygen species], growth factors). Signaling pathways with prosurvival functions frequently observed to be activated in plaque VSMCs include p38, ERK1/2 (extracellular signal-regulated kinases 1/2), and Akt. [13] [14] [15] [16] [17] We investigated the activity of each of these kinases by immunoblot analysis of whole cell lysates from control GFP-VSMCs and SPRR3-VSMCs. Western blot analysis indicated that Akt phosphorylation at Ser473 was increased in SPRR3-VSMCs relative to GFP-VSMCs ( Figure 6A ) and in WT-VSMCs relative to SPRR3-KO VSMCs ( Figure 6B ). However, there was no difference in phosphorylated p38 or phosphorylated ERK1/2 levels in GFP-VSMCs or SPRR3-VSMCs, indicating that SPRR3 was not a downstream effector of these pathways ( Figure X in the online-only Data Supplement).
Several growth factors have been implicated in Akt activation in lesion VSMCs, including IGF-1 18, 19 . We investigated whether IGF-1 (insulin-like growth factor 1) may enhance SPRR3-mediated increases in phosphorylated Akt (pAkt) levels. Treatment of GFP-or SPRR3-VSMCs with IGF-1 triggered a proportionally equal increase in pAkt levels, indicating that SPRR3 was not a downstream effector of Figure 6C ). Addition of a PI3K (phosphatidylinositol 3-kinase)/Akt inhibitor (Ly294002) abolishes pAkt in both GFP-VSMCs and SPRR3-VSMCs, indicating that SPRR3 increases pAkt levels in a canonical, PI3K/Akt-dependent manner ( Figure 6C ). To assess whether the observed SPRR3-mediated survival benefits were dependent on Akt activity, we evaluated GFP-and SPRR3-VSMCs with and without Ly294002 and assessed cell death using TUNEL staining. The prosurvival effect of SPRR3-overexpression was abolished in cells treated with Ly294002, in which we detected a 49% increase (P=0.005) in TdT labeling compared with untreated cells (Figure 6D and 6E) .
IGF-1 (
Discussion
We have identified SPRR3 as an atheroprotective factor in VSMCs that is uniquely upregulated in mouse and human atherosclerotic lesions. Global knockout of SPRR3 in the mouse led to significantly increased atheroma burden along with reduced survival of VSMCs, but not of ECs. In addition, transplantation of SPRR3 +/+ BM cells into mice lacking SPRR3 did not alter atherosclerosis development. Intriguingly, SPRR3 expression in cultured VSMCs was positively associated with Akt activity. In vitro studies in VSMCs challenged with oxidative stress indicated an SPRR3-mediated survival benefit. When these studies were conducted in the presence of a PI3K/ Akt inhibitor, the SPRR3-mediated survival benefit was lost. Our findings indicated that SPRR3 expression in VSMCs played a critical role in Akt-mediated survival signaling in atherosclerotic lesions, protecting the atheroma from excessive VSMC apoptosis and leading to higher VSMC content in the fibrous cap.
Most studies intent on identification of atheroprotective genes have investigated ECs or immune cells. In ECs, studies have focused on key differences between gene expression in arterial tissue exposed to laminar versus turbulent flow, as exposure to turbulent flow is associated with increased risk of atheroma initiation. [20] [21] [22] [23] [24] [25] In immune cells, studies have investigated the role of genes that either reduce inflammation or improve cholesterol homeostasis, both interventions leading to reduced lesion size and complexity. [26] [27] [28] [29] Less is understood, however, about VSMC-specific atheroprotective genes. A few studies have investigated regulation of VSMC proliferation and intima-media thickness, mechanisms most critical at atheroma initiation. [30] [31] [32] More work is needed in investigating later stages of atheroma development where VSMC survival and maintenance of a synthetic phenotype may be more important, as these characteristics are critical for regulation of atheroma progression and fibrous cap stability. 33 Previously, Bennett's group demonstrated accelerated atheroma progression and a vulnerable phenotype in an inducible diphtheria toxin-driven mouse model of chronic, low-level VSMC apoptosis. 34 A potential explanation for this effect may be that an increase in VSMC apoptosis within the lesion will, in turn, increase cellular debris and other proinflammatory stimuli, recruiting macrophages and other immune cells to the lesion and accelerating foam cell formation. The effect may also suggest a protective role of VSMCs in the lesion, either through an unidentified secreted factor(s) or through delay of lipid deposition or macrophage entry. Although the mechanism(s) driving atheroma progression in lesions experiencing chronic VSMC apoptosis remains uncharacterized, Bennett's model emphasizes the importance of reducing VSMC apoptosis in regulation of atheroma size and composition. Despite the potential for use in delaying atheroma progression, no one has previously identified a lesion-specific regulator of VSMC survival.
SPRR3 knockout mice demonstrated altered VSMC survival in atheromas, whereas VSMCs in normal arterial tissue remained unaffected. Cells residing in the atheroma microenvironment encounter a myriad of stressors, putting them at increased risk of cell death. Stressors in the atheroma milieu include extracellular cholesterol and oxidized fatty acids, hypoxic conditions, rising ROS levels, and an array of inflammatory cytokines released by both activated ECs and macrophages. [35] [36] [37] [38] [39] The critical role VSMCs play in synthesis and subsequent maintenance of the barrier between these atheroma components and the circulation makes them an indispensible part of a stable plaque. Our data suggested that SPRR3 activity specifically in the atheroma may be part of an adaptive response to the injurious atheroma microenvironment by protecting VSMCs from death.
The PI3K/Akt pathway is an important regulator of cell survival. We showed that upregulation of SPRR3 in VSMCs was positively associated with increased Akt phosphorylation; and the reverse was also true, as VSMCs lacking SPRR3 had reduced pAkt levels. The SPRR family has, until recently, been recognized solely as a family of structural proteins providing support against high levels of mechanical strain. Some evidence has been published showing an association between increased SPRR3 levels and increased colorectal or breast cancer cell proliferation and Akt activity 7, 40 ; however, the mechanism for this phenotype or whether SPRR3 plays a role in oncogenesis has not yet been studied. Previous work has not identified a kinase-interacting role for SPRR family members. Thus, our current study uncovered a novel function for SPRR3 through activation of Akt to promote VSMC survival. Consistent with our hypothesis, other groups have identified prosurvival activity for SPRR family members. One investigation suggested that SPRR2a may modulate p53 transcription and p300 acetylation status in cholangiocarcinoma cells leading to reduced apoptosis. 41 Another group demonstrated that SPRR1a is upregulated downstream of the gp130 pathway in cardiomyocytes and protected against ischemic stress-induced apoptosis. 42 Future studies will focus on elucidation of the precise molecular mechanism by which SPRR3 may activate Akt specifically in plaque VSMCs, allowing a targeted intervention aimed at VSMC protection within the lesion.
Our survival studies, in which cultured VSMCs under oxidative stress were treated with a PI3K/Akt inhibitor, showed that pAkt upregulation was required for an SPRR3-mediated survival benefit. The SPRR3-dependent increase in Akt activity occurs independently of the insulin-like growth factor signaling pathway, as treatment with IGF-1 results in a proportional increase in pAkt across cell types. Tissue-specific activators of Akt are rare. To our knowledge, the only other protein that promotes Akt activity in a tissue-specific manner is T-cell leukemia/lymphoma 1. Expressed only in lymphoid tissue, T-cell leukemia/lymphoma 11 was discovered because of its pro-to-oncogene activity in human T-cell malignancies. 43 T-cell leukemia/lymphoma 11 increases Akt activation by binding the PH domain of Akt and causing a conformational change to promote Ser473 phosphorylation.
44 SPRR3 represents, to our knowledge, the first VSMC-specific activator of Akt and one that has the potential to mediate the VSMC atherosclerosis response.
Because chronic VSMC apoptosis leads to accelerated atherosclerosis, and SPRR3-mediated protection was lost after PI3K/Akt inhibition, the increase in atheroma burden in SPRR3 knockout mice may be at least partly attributable to altered Akt activity. Global knockout of Akt1 (the most widely expressed isoform of Akt) or Akt3 in ApoE-null mice leads to accelerated atheroma progression. 26, 45 Global Akt2 knockout on an low-density lipoprotein receptor-deficient background, meanwhile, leads to smaller, more complex atheromas with a 6-fold increase in percentage of TUNEL-positive cells and reduced cap VSMC content. 46 BM transplantation studies revealed that Akt1 deficiency in the BM alone is insufficient to increase the atherosclerotic phenotype in ApoE-null mice, indicating that the increased atherosclerosis is probably because of changes in the arterial cells. 45 Akt1 −/− mice experience reduced survival of ECs, macrophages, and VSMCs, and Akt1 loss is associated with increased inflammatory molecule expression (eg, interleukin-6, tumor necrosis factor-α) in the artery wall. 45, 47 Mice experiencing a global knockout of Akt3 also exhibit increased atherosclerosis on an ApoE-null background. 26 Loss of Akt3 did not affect macrophage survival, but foam cell formation was increased in Akt3 −/− macrophages in vitro and rescue of Akt3 in the BM of Akt3-null mice was atheroprotective. Although both the Akt1 and Akt3 studies examined the specific role of BM-derived cell expression of Akt relative to arterial expression, neither study attempted to separate the role of VSMC expression of Akt from that of ECs. In vitro studies have indicated that VSMCs isolated from atheroma in humans and mice have downregulated activity of Akt pathway members (eg, FoxO3, GSK3-β) and are more prone to apoptosis. 13 In our study, upregulation of Akt activity by SPRR3 may be stabilizing atheroma VSMCs and thereby slowing plaque progression.
Altogether, we show loss of SPRR3 in the plaque accelerates atheroma progression while reducing VSMC prosurvival signals. Although atheroprotective signaling has been identified in areas of shear stress, these pathways are generally downregulated in atheroma-prone regions experiencing turbulent mechanical stress. Our findings demonstrated that atheroprotective signals also occur in atheroma-resident cells. Moreover, the atheroma-specific expression pattern provided a unique opportunity for targeted intervention in atheroma VSMCs. Our data suggested that lesion VSMC expression of SPRR3 provided a defense mechanism in atherosclerotic plaques, in which prosurvival Akt signaling was promoted to stabilize these cells under mechanical strain, slowing plaque progression. Identification of intermediary signaling interactions may provide key targets for future therapy of patients with early onset or advanced stages of CVD.
